PDE3A and diabetic neuropathy: Cilostazol has demonstrated potential as a pharmacological agent for treating both PAD and diabetic neuropathy due to its ability to inhibit phosphodiesterase-3A, promote vasodilation, inhibit platelet aggregation, and increase cAMP levels.